Have a personal or library account? Click to login
Prevalence, Predictors, and Outcomes of Resistant Hypertension in Egyptian Population Cover

Prevalence, Predictors, and Outcomes of Resistant Hypertension in Egyptian Population

Global Heart
Volume 18 (2023): Issue 1
By: Mohamed Khalfallah,  Ayman Elsheikh,  Ahmad Eissa and  Basma Elnagar  
Open Access
|Jun 2023

References

  1. 1Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017; 317(2): 165–182.
    Back to article
  2. 2Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. The Lancet. 2021; 398: 957–980. DOI: 10.1016/S0140-6736(21)01330-1
    Back to article
  3. 3Ostchega Y, Fryar CD, Nwankwo T, Nguyen DT. Hypertension prevalence among adults aged 18 and over: United States, 2017–2018. NCHS Data Brief. 2020; 364: 1–8.
    Back to article
  4. 4Kirkland EB, Heincelman M, Bishu KG, et. al. Trends in healthcare expenditures among US adults with hypertension: National estimates, 2003–2014. J Am Heart Assoc. 2018; 7: e008731. DOI: 10.1161/JAHA.118.008731
    Back to article
  5. 5World Health Organization RoftEM. New round of stepwise survey 2016–2017 to start in Egypt. World Health Organization RoftEM; 2017.
    Back to article
  6. 6El Faramawy A, Youssef G, El Aroussy W, et al. Registry of the Egyptian specialized hypertension clinics: Patient risk profiles and geographical differences. J Hum Hypertens. 2020; 34(7): 520–527. DOI: 10.1038/s41371-019-0265-0
    Back to article
  7. 7Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: Detection, evaluation, and management: A scientific statement from the American Heart Association. Hypertension. 2018; 72(5): e53–e90.
    Back to article
  8. 8Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019; 73(2): 424–431. DOI: 10.1161/HYPERTENSIONAHA.118.12191
    Back to article
  9. 9Hwang AY, Dietrich E, Pepine CJ, Smith SM. Resistant hypertension: Mechanisms and treatment. Curr Hypertens Rep. 2017; 19(7): 56. DOI: 10.1007/s11906-017-0754-x
    Back to article
  10. 10Laukkanen JA, Jennings JR, Kauhanen J, Mäkikallio TH, Ronkainen K, Kurl S. Relation of systemic blood pressure to sudden cardiac death. Am J Cardiol. 2012; 110(3): 378–382. DOI: 10.1016/j.amjcard.2012.03.035
    Back to article
  11. 11SPRINT Research Group, Lewis CE, Fine LJ, et al. Final report of a trial of intensive versus standard blood-pressure control. N Engl J Med. 2021; 384(20): 1921–1930. DOI: 10.1056/NEJMoa1901281
    Back to article
  12. 12Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: A meta-analysis of data from 3.2 million patients. Heart. 2019; 105(2): 98–105. DOI: 10.1136/heartjnl-2018-313599
    Back to article
  13. 13Dean AG, Arner TG, Sunki GG, Friedman R, Lantinga M, Sangam S, et al. Epi Info™, a database and statistics program for public health professionals. Atlanta, GA, USA: CDC; 2011.
    Back to article
  14. 14Naseem R, Adam AM, Khan F, et al. Prevalence and characteristics of resistant hypertensive patients in an Asian population. Indian Heart J. 2017; 69(4): 442–446. DOI: 10.1016/j.ihj.2017.01.012
    Back to article
  15. 15Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, et al. Recommendations for chamber quantification: A report from the American Society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2015; 18: 1440–1463. DOI: 10.1016/j.echo.2005.10.005
    Back to article
  16. 16Doroszko A, Janus A, Szahidewicz-Krupska E, Mazur G, Derkacz A. Resistant Hypertension. Adv Clin Exp Med. 2016; 25(1): 173–183. DOI: 10.17219/acem/58998
    Back to article
  17. 17Parasher A, Jhamb R. Resistant hypertension: A review. International Journal of Advances in Medicine. 2021; 8(9): 1433. DOI: 10.18203/2349-3933.ijam20213252
    Back to article
  18. 18Sinnott SJ, Smeeth L, Williamson E, Douglas IJ. Trends for prevalence and incidence of resistant hypertension: Population based cohort study in the UK 1995–2015. BMJ. 2017; 358: j3984. DOI: 10.1136/bmj.j3984
    Back to article
  19. 19Gijón-Conde T, Graciani A, Banegas JR. Resistant hypertension: Demography and clinical characteristics in 6,292 patients in a primary health care setting. Rev Esp Cardiol (Engl Ed). 2014; 67(4): 270–276. DOI: 10.1016/j.recesp.2013.09.029
    Back to article
  20. 20Muxfeldt ES, Chedier B, Rodrigues CIS. Resistant and refractory hypertension: Two sides of the same disease? J Bras Nefrol. 2019; 41(2): 266–274. DOI: 10.1590/2175-8239-jbn-2018-0108
    Back to article
  21. 21Nansseu JR, Noubiap JJ, Mengnjo MK, et al. The highly neglected burden of resistant hypertension in Africa: A systematic review and meta-analysis. BMJ Open. 2016; 6(9): e011452. DOI: 10.1136/bmjopen-2016-011452
    Back to article
  22. 22Thinyane KH, Mothebe T, Sooro M, Namole LD, Cooper V. An observational study of hypertension treatment and patient outcomes in a primary care setting. Pan Afr Med J. 2015; 20: 424. DOI: 10.11604/pamj.2015.20.424.5040
    Back to article
  23. 23Cherif AB, Taleb A, Temmar M, Debbih ND, Chibane A, Bouafia M. PP. 40.21: Prevalence and causes of resistant hypertension in specialized consultation in the area of blida (Algeria). Journal of Hypertension. 2015; 33: e498. DOI: 10.1097/01.hjh.0000468959.33385.5e
    Back to article
  24. 24Asgedom SW, Amanuel K, Gidey MT, Niriayo YL, Gidey K, Atey TM. Treatment resistant hypertension among ambulatory hypertensive patients: A cross sectional study. PLoS One. 2020; 15(4): e0232254. DOI: 10.1371/journal.pone.0232254
    Back to article
  25. 25Kuntonda DK, Lepira FB, Lubenga Y, et al. True resistant hypertension among treated hypertensive black patients. A clinical-based cross-sectional study. World J Cardiovasc Dis. 2020; 10(05): 278–293. DOI: 10.4236/wjcd.2020.105026
    Back to article
  26. 26Chia YC, Ching SM. Prevalence and predictors of resistant hypertension in a primary care setting: A cross-sectional study. BMC Fam Pract. 2014; 15: 131. DOI: 10.1186/1471-2296-15-131
    Back to article
  27. 27Sarafidis PA, Georgianos PI, Zebekakis PE. Comparative epidemiology of resistant hypertension in chronic kidney disease and the general hypertensive population. Semin Nephrol. 2014; 34(5): 483–491. DOI: 10.1016/j.semnephrol.2014.08.001
    Back to article
  28. 28Buhnerkempe MG, Prakash V, Botchway A, et al. Adverse health outcomes associated with refractory and treatment-resistant hypertension in the chronic renal insufficiency cohort. Hypertension. 2021; 77(1): 72–81. DOI: 10.1161/HYPERTENSIONAHA.120.15064
    Back to article
  29. 29Leung AA, Williams JVA, Tran KC, Padwal RS. Epidemiology of resistant hypertension in Canada. Can J Cardiol. 2022; 38(5): 681–687. DOI: 10.1016/j.cjca.2022.01.029
    Back to article
  30. 30Campese VM, Mitra N, Sandee D. Hypertension in renal parenchymal disease: Why is it so resistant to treatment? Kidney Int. 2006; 69(6): 967–973. DOI: 10.1038/sj.ki.5000177
    Back to article
  31. 31Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. Am J Med. 2014; 127(1): 71–81.e1. DOI: 10.1016/j.amjmed.2013.07.038
    Back to article
  32. 32Egan BM, Zhao Y, Axon RN, Brzezinski WA, Ferdinand KC. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation. 2011; 124(9): 1046–1058. DOI: 10.1161/CIRCULATIONAHA.111.030189
    Back to article
  33. 33Desai R, Park H, Brown JD, Smith SM. Risk of obstructive sleep apnea in adults with resistant hypertension. Pharmacoepidemiology. 2022; 1(1): 26-32. DOI: 10.3390/pharma1010003
    Back to article
  34. 34Lloberes P, Lozano L, Sampol G, et al. Obstructive sleep apnoea and 24-h blood pressure in patients with resistant hypertension. J Sleep Res. 2010; 19(4): 597–602. DOI: 10.1111/j.1365-2869.2010.00839.x
    Back to article
  35. 35Dobrowolski P, Prejbisz A, Klisiewicz A, et al. Determinants of concentric left ventricular hypertrophy in patients with resistant hypertension: RESIST-POL study. Hypertens Res. 2015; 38(8): 545–550. DOI: 10.1038/hr.2015.39
    Back to article
  36. 36Cao G, Chen C, Lin Q, et al. Prevalence, clinical characteristics and echocardiography parameters of non-resistant, resistant and refractory hypertension in Chinese. Postgrad Med. 2017; 129(2): 187–192. DOI: 10.1080/00325481.2017.1272398
    Back to article
  37. 37Jin CN, Liu M, Sun JP, et al. The prevalence and prognosis of resistant hypertension in patients with heart failure. PLoS One. 2014; 9(12): e114958. DOI: 10.1371/journal.pone.0114958
    Back to article
  38. 38Chun KH, Lee CJ, Oh J, et al. Prevalence and prognosis of the 2018 vs 2008 AHA definitions of apparent treatment-resistant hypertension in high-risk hypertension patients. J Clin Hypertens (Greenwich). 2020; 22(11): 2093–2102. DOI: 10.1111/jch.14043
    Back to article
  39. 39Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012; 125(13): 1635–1642. DOI: 10.1161/CIRCULATIONAHA.111.068064
    Back to article
  40. 40Cushman WC, Ford CE, Cutler JA, et al. Success and predictors of blood pressure control in diverse North American settings: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002; 4(6): 393–404. DOI: 10.1111/j.1524-6175.2002.02045.x
    Back to article
  41. 41Thomas G, Xie D, Chen HY, et al. Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: Report from the chronic renal insufficiency cohort study. Hypertension. 2016; 67(2): 387–396. DOI: 10.1161/HYPERTENSIONAHA.115.06487
    Back to article
  42. 42Faselis C, Doumas M, Papademetriou V. Common secondary causes of resistant hypertension and rational for treatment. Int J Hypertens. 2011; 2011: 236239. DOI: 10.4061/2011/236239
    Back to article
DOI: https://doi.org/10.5334/gh.1211 | Journal eISSN: 2211-8179
Journal RSS Feed
Language: English
Submitted on: Oct 4, 2022
Accepted on: May 16, 2023
Published on: Jun 14, 2023
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
prevalence,
predictors,
outcomes,
resistant hypertension,
Egyptian population

© 2023 Mohamed Khalfallah, Ayman Elsheikh, Ahmad Eissa, Basma Elnagar, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 18 (2023): Issue 1Next article